Literature DB >> 9457035

Factors associated with limb loss despite a patent infrainguinal bypass graft.

C G Carsten1, S M Taylor, E M Langan, M M Crane.   

Abstract

Lower-extremity limb salvage should parallel infrainguinal bypass graft patency. To determine factors associated with limb loss despite a patent bypass, we reviewed 191 consecutive infrainguinal bypasses in 158 patients followed prospectively over 42 months. In this series of 176 (92%) vein grafts, 15 (8%) expanded polytetrafluoroethylene grafts, 122 (64%) tibial artery bypasses, and 170 (89%) bypasses placed for limb salvage, 29 major lower-extremity (above-knee or below-knee) amputations were performed in 29 patients, 12 because of ischemia after graft thrombosis and 17 (9% of series) due to progression of soft tissue infection/necrosis despite a functioning bypass. Primary and secondary 36-month vein graft patencies by life-table analysis were 61 per cent and 81 per cent, respectively. When the 17 cases of limb loss were compared to the rest of the series, nonstatistically significant variables included male sex [11 (65%) vs 79 (56%); P = 0.608] and diabetes [12 (71%) vs 80 (57%); P = 0.310]. Statistically significant variables included black race [9 (53%) vs 39 (28%); P = 0.048]; chronic renal failure [6 (35%) vs 12 (9%); P = 0.005], placement to a tibial/pedal artery [15 (88%) vs 107 (62%); P = 0.034], distal anastomosis to the anterior tibial/dorsalis pedis (AT/DP) artery [8 (47%) vs 27 (16%); P = 0.004], and grafts requiring late revision [7 (41%) vs 22 (13%); P = 0.006]. Thirteen (76%) extremities had an intact pedal arch. Nine amputations were performed within 30 days (early group), and eight were performed from 45 days to 20 months (median, 8 months) after bypass placement (late group). The most common primary causes of limb loss in the early group were overwhelming progression of soft-tissue infection despite patent bypass (n = 4; 44%) and insufficient runoff in the foot (n = 3; 33%). In the late group, amputation most often followed long treatment of a chronic proximal diabetic neuropathic foot ulcer with osteomyelitis. Five (63%) grafts in this group were anastomosed to the AT/DP arteries. These data suggest that patients with chronic renal failure, chronic neuropathic heel ulcers, and an AT/DP bypass are at greater risk for amputation despite a working bypass, especially if the graft develops a hemodynamically significant stenosis. Careful judgment and patient selection under these circumstances are thus justified.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9457035

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  5 in total

1.  Failure to achieve clinical improvement despite graft patency in patients undergoing infrainguinal lower extremity bypass for critical limb ischemia.

Authors:  Jessica P Simons; Philip P Goodney; Brian W Nolan; Jack L Cronenwett; Louis M Messina; Andres Schanzer
Journal:  J Vasc Surg       Date:  2010-04-24       Impact factor: 4.268

2.  Cost-effectiveness of revascularization for limb preservation in patients with end-stage renal disease.

Authors:  Neal R Barshes; Panos Kougias; C Keith Ozaki; Philip P Goodney; Michael Belkin
Journal:  J Vasc Surg       Date:  2014-03-20       Impact factor: 4.268

Review 3.  A review of the surgical management of heel pressure ulcers in the 21st century.

Authors:  David C Bosanquet; Ann M Wright; Richard D White; Ian M Williams
Journal:  Int Wound J       Date:  2015-02-16       Impact factor: 3.315

Review 4.  miR-210: the master hypoxamir.

Authors:  Yuk C Chan; Jaideep Banerjee; Sang Yong Choi; Chandan K Sen
Journal:  Microcirculation       Date:  2012-04       Impact factor: 2.628

Review 5.  The comparative efficacy of angiosome-directed and indirect revascularisation strategies to aid healing of chronic foot wounds in patients with co-morbid diabetes mellitus and critical limb ischaemia: a literature review.

Authors:  Benedictine Y C Khor; Pamela Price
Journal:  J Foot Ankle Res       Date:  2017-06-28       Impact factor: 2.303

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.